Yamada S, Yoshioka R, Shibatani T
Pharmaceutical Development Research Laboratory, Tanabe Seiyaku Co., Ltd., Osaka, Japan.
Chem Pharm Bull (Tokyo). 1997 Dec;45(12):1922-7. doi: 10.1248/cpb.45.1922.
Practical preparation methods of an optically active intermediate of diltiazem, (+)-(2S,3S)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy- 2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one [(+)-7], have been developed by the use of physicochemical and chemical resolutions. 1) The salt of (+/-)-7 with 3-amino-4-hydroxy-benzenesulfonic acid (AHS), was found to exist as a conglomerate and could be reproducibly resolved into (+)-7.AHS and (-)-7.AHS of 94-98% ee by a preferential crystallization procedure. 2) (+)-(1R)-3-Bromocamphor-9-sulfonic acid [(+)-BCS] was found to be an efficient resolving agent for (+/-)-7 and the diastereomeric resolution provided (+)-7.(+)-BCS.2H2O salt in > 43% yield and > 97% ee by fractional crystallization. It is presumed that the crystal water of (+)-7.(+)-BCS.2H2O plays an important role in the selective crystallization during this efficient resolution.
通过物理化学拆分和化学拆分,已开发出地尔硫卓光学活性中间体(+)-(2S,3S)-5-[2-(二甲基氨基)乙基]-2,3-二氢-3-羟基-2-(4-甲氧基苯基)-1,5-苯并硫氮杂䓬-4(5H)-酮[(+)-7]的实用制备方法。1)发现(±)-7与3-氨基-4-羟基苯磺酸(AHS)形成的盐以聚集体形式存在,通过优先结晶法可重复拆分为对映体过量(ee)值为94-98%的(+)-7·AHS和(-)-7·AHS。2)发现(+)-(1R)-3-溴樟脑-9-磺酸[(+)-BCS]是(±)-7的有效拆分剂,通过分步结晶,非对映体拆分得到产率>43%、ee值>97%的(+)-7·(+)-BCS·2H₂O盐。据推测,(+)-7·(+)-BCS·2H₂O的结晶水在这种高效拆分过程中的选择性结晶中起重要作用。